Expanded access to vepugratinib for FGFR3-altered tumors
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial provides expanded access to vepugratinib, an experimental drug that targets a specific gene change (FGFR3) found in some solid tumors, including bladder cancer. It’s for people who have run out of standard treatment options and cannot join another study of the same drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic bladder cancer or another solid tumor with a specific change in the FGFR3 gene.
- You have already tried all other approved treatments, including erdafitinib for bladder cancer.
- You are not able to join another ongoing clinical trial testing vepugratinib.
- You do not have a serious eye problem (like a corneal or retinal disorder) unless it's minor and symptom-free.
- You do not have significant heart disease, and you are not pregnant or planning to become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called Vepugratinib for people with advanced urinary tract cancer that has a specific change in the FGFR3 gene. It may be an option if you haven't had other treatments for advanced cancer and are looking for a new approach.
This study tests a new pill, vepugratinib, for people whose cancer has a specific change in a gene called FGFR3. The drug targets this gene change to try to slow or shrink the cancer, and may be an option if standard treatments have not worked.
This trial tests a new drug, PF-08634404, either by itself or together with another drug called enfortumab vedotin, for people with advanced bladder cancer that has spread. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
This trial tests a procedure called therapeutic plasma exchange (TPE) combined with the drugs enfortumab vedotin and pembrolizumab for people with advanced bladder cancer that has stopped responding to standard treatments. The goal is to see if TPE helps the drugs work better.
This trial tests a combination of two drugs: pemigatinib (targets FGFR gene changes) and an immunotherapy (checkpoint inhibitor) for people with advanced solid tumors that have FGFR mutations. It may be a good option if standard treatments have failed and you have already tried immunotherapy.
Hear when a new Urinary Bladder Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.